Prevalence of Prostate Specific Antigen Testing for Prostate Cancer in Elderly Men
Authors:
- 1 June 2006
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 175 (6) , 2078-2082
Abstract
We investigated the prevalence and outcome of PSA testing for prostate cancer screening or diagnosis in elderly men 75 years or older at our academic medical center. A cross-sectional study design was used to identify all men 75 years or older who underwent a PSA test through the family medicine or internal medicine service at our institution between January 1, 1998 and June 30, 2004. All patients with a suspected (PSA less than 0.1 ng/ml) or confirmed prior diagnosis of prostate cancer were excluded. The prevalence of PSA testing was then compared to that in younger age groups (45 to 54, 55 to 64 and 65 to 74 years). We then examined the frequency and nature of further evaluation and treatment performed in men following the PSA test. The 8,787 male patients who were 75 years or older generated a total of 82,672 visits in the 5.5-year period. Of these patients 505 (5.7%) underwent at least 1 PSA test. The prevalence of PSA testing in the younger age groups was 10.3% (1,769 of 17,175) in patients 45 to 54 years old, 14.9% (2,052 of 13,772) in those 55 to 64 years old and 11.8% (1,258 of 10,661) in those 65 to 74 years old (chi-square test p <0.001). Of these patients 98 of 343 (28.6%) with PSA between 0.1 and 4 ng/ml were referred to a urologist at our institution and 3 underwent biopsy. None had a prostate cancer diagnosis. Of the 162 patients with PSA more than 4 ng/ml 84 (51.9%) were referred to a urologist. Only 10 of the 84 patients (11.9%) who were referred to a urologist underwent prostate biopsy. Six of the 10 men (60%) were diagnosed with prostate cancer, including 1 with a Gleason 6 tumor, 1 with a Gleason 7 tumor and 4 who were found to have tumors with a Gleason score of 8 or greater. All patients received androgen deprivation therapy, except 1 who received local external beam radiation therapy. An additional patient was diagnosed by biopsy of a vertebral lesion and he received hormone therapy. At a median followup of 51 months (range 28 to 72) 4 of 7 men (57%) were alive with disease. PSA testing for prostate cancer screening and diagnosis appear to decrease with advancing age. A small but significant proportion of men who are 75 years or older continue to undergo PSA testing. Abnormal PSA results do not always result in further evaluation and therapy for prostate cancer in elderly men. The establishment of firm guideline recommendations regarding PSA testing and further evaluation for prostate cancer in elderly men, perhaps based on individualized geriatric assessment, may be helpful.Keywords
This publication has 16 references indexed in Scilit:
- THE PROSTATE SPECIFIC ANTIGEN ERA IN THE UNITED STATES IS OVER FOR PROSTATE CANCER: WHAT HAPPENED IN THE LAST 20 YEARS?Journal of Urology, 2004
- Age-Related Disparities in Cancer Screening: Analysis of 2001 Behavioral Risk Factor Surveillance System DataThe Annals of Family Medicine, 2004
- Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per MilliliterNew England Journal of Medicine, 2004
- 130: PSA Testing Utilization by Urologists and Primary Care Physicians: Data from the 2000 National Ambulatory Medical Care SurveyJournal of Urology, 2004
- Prostate-Specific Antigen Screening in Elderly MenJNCI: Journal of the National Cancer Institute, 2003
- Is there age bias in the treatment of localized prostate carcinoma?Cancer, 2003
- Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2002
- American Cancer Society Guidelines for the Early Detection of CancerCA: A Cancer Journal for Clinicians, 2002
- Screening for prostate cancer. A decision analytic view1994
- Results of Conservative Management of Clinically Localized Prostate CancerNew England Journal of Medicine, 1994